Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4290 | Talabostat Mesylate plus Pembrolizumab Wiki | 0.71 |
| drug1132 | ConvP Wiki | 0.71 |
| drug1612 | FFP Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D055752 | Small Cell Lung Carcinoma NIH | 0.82 |
| D018358 | Neuroendocrine Tumors NIH | 0.41 |
| D011471 | Prostatic Neoplasms NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0030357 | Small cell lung carcinoma HPO | 0.82 |
| HP:0100634 | Neuroendocrine neoplasm HPO | 0.41 |
| HP:0012125 | Prostate cancer HPO | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002664 | Neoplasm HPO | 0.10 |
Navigate: Correlations HPO
There are 2 clinical trials
An open-label, multicenter, Phase 1b/2 study to determine the composite response rate of BXCL701 administered orally and daily, combined wit PEMBRO, in patients with mCRPC enrolled in Stage 2, with either Small Cell Neuroendocrine Prostate Cancer(SCNC)(Cohort A) or adenocarcinoma phenotype (Cohort B). This study will also assess other efficacy parameters as well as the safety of the combined treatment. This study will consist of two (2) stages. Lead-in Stage, in which the safety and tolerability of the combination will be assessed and confirmed. And the Efficacy Stage, in which patients will be treated with BXCL701 combined with PEMBRO.
Description: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; circulating tumor cell (CTC) conversion from >5/7.5 mL to <5/7.5 mL12; and a greater than 50% prostate-specific antigen (PSA) decline from baseline.
Measure: Estimate the composite response rate of the combination of BXCL701 + PEMBRO Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro determined by radiographic evidence.
Measure: Estimate the median radiographic progression-free survival (rPFS) of the combination of BXCL701 and PEMBRO in Cohort A and B Time: up to 36 monthsDescription: The median time frame with progression-free survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median PSA progression-free survival (PSA PFS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The median time frame with overall survival with the use of BXCL701 in combination with Pembro
Measure: Estimate the median overall survival (OS) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: The timeframe in which the tumor reacts to BXCL701 in combination with Pembro
Measure: Estimate the median duration of response (DOR) of the combination of BXCL701 and PEMBRO in Cohort A and B. Time: up to 36 monthsDescription: Determines the frequency and severity of known and unknown adverse events with the use of BXCL701 in combination with Pembro
Measure: Determine the risk profile of the use of BXCL701 in combination with PEMBRO. Time: up to 36 monthsThis phase I trial identifies the best dose and side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer that has spread (extensive-stage small cell lung cancer). Entinostat and etoposide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving entinostat in combination with atezolizumab, carboplatin and etoposide may work better than atezolizumab, carboplatin and etoposide alone.
Description: The Bayesian optimal interval (BOIN) design will be used to find the MTD based on safety.
Measure: Maximum tolerated dose (MTD) Time: Up to 21 daysDescription: Defined by Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by frequency and magnitude.
Measure: Grade 3/4 adverse event rate Time: Up to 30 daysDescription: The proportion of participants who receive 3 or more cycles of the combination, will be calculated with a 90% confidence interval.
Measure: Number of cycles received of the combination of entinostat, atezolizumab, carboplatin, and etoposide Time: Up to cycle 4 (1 cycle = 21 days)Description: Defined as the proportion of patients alive and without disease progression after 9 months from study enrollment. The 9 month PFS rate will be estimated with a 90% confidence interval. The Kaplan Meier estimator will be used to estimate survival curves.
Measure: 9-month progression free survival (PFS) rate Time: 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports